High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial.
Luis Patricio MaskinIgnacio BonelliGabriel Leonardo OlarteFernando PalizasAgostina E VeloMaría Fernanda LurbetPablo LovazzanoSophia KotsiasShiry AttieIgnacio Lopez SaubidetNatalio D BaredesMariano SettenPablo Oscar RodriguezPublished in: Journal of intensive care medicine (2021)
Among patients with ARDS due to COVID-19, the use of higher doses of dexamethasone compared with the recommended low-dose treatment did not show an increase in VFD. However, the higher dose significantly improved the time required to liberate them from the ventilator.
Keyphrases
- acute respiratory distress syndrome
- low dose
- open label
- clinical trial
- mechanical ventilation
- extracorporeal membrane oxygenation
- high dose
- coronavirus disease
- sars cov
- double blind
- phase iii
- study protocol
- squamous cell carcinoma
- randomized controlled trial
- placebo controlled
- cross sectional
- radiation therapy
- drug induced
- replacement therapy